Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login

Adding clopidogrel to aspirin does not reduce mortality for patients with drug-eluting coronary stents

Addition of clopidogrel to aspirin therapy does not reduce the rate of myocardial infarction or cardiac death among patients who have received drug-eluting coronary stents, according to a study published online in the New England Journal of Medicine (15 March 2010).

Some 2,700 patients, who had received such a stent and been free of cardiac or cerebrovascular events for at least 12 months, were randomised to receive aspirin and clopidogrel, or aspirin alone.

After two years, the cumulative risk of myocardial infarction or cardiac death was not significantly different between the two groups.

Citation: Clinical Pharmacist URI: 11004594

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.